NCIMMUNE LEADING EARLY CANCER DETECTION

We invite you to view our news/press releases below.

Date Title Link/PDF
December 6 Positive Interim Data from NHS Screening Trial Positive Interim Data from NHS Screening Trial
October 11 Appointment of Carsten Schroeder as Non-Executive Director Appointment of Carsten Schroeder as Non-Executive Director
September 22 Maarten Brusse appointed Chief Commercial Officer Asia Maarten Brusse appointed Chief Commercial Officer Asia
September 20 New Data Highlights Effectiveness of EarlyCDT®-Lung in Assessing Lung Cancer Risk of Nodules Detected During CT Screening - Publication in Journal of Thoracic Oncology New Data Highlights Effectiveness of EarlyCDT®-Lung in Assessing Lung Cancer Risk of Nodules Detected During CT Screening - Publication in Journal of Thoracic Oncology
August 17 Andrew Millet appointed to the Board as Chief Financial Officer Andrew Millet appointed to the Board as Chief Financial Officer
July 15 CE Mark for EarlyCDT®-Lung CE Mark for EarlyCDT®-Lung
July 4 Oncimmune Signs Research Agreements in Ovarian and Liver Cancer - Samples Sourced to Validate EarlyCDT® in New Indications Oncimmune Signs Research Agreements in Ovarian and Liver Cancer - Samples Sourced to Validate EarlyCDT® in New Indications
May 25 Oncimmune Signs Three Further US Distribution Agreements Oncimmune Signs Three Further US Distribution Agreements
May 13 Patent Update Patent Update
March 18 Oncimmune Signs Agreement with Accu Reference Oncimmune Signs Agreement with Accu Reference
March 3 Oncimmune Signs Agreement with Leading Provider of Preventative Health Screenings Oncimmune Signs Agreement with Leading Provider of Preventative Health Screenings
January 20 Oncimmune Appoints Greg Stanley as President of Commercial Operations Oncimmune Appoints Greg Stanley as President of Commercial Operations
Date Title Link/PDF
December 5 Pathology, Inc. Introduces Blood Test to Aid in the Early Detection of Lung Cancer Pathology, Inc. Introduces Blood Test to Aid in the Early Detection of Lung Cancer
November 13 Enzo Biochem's Clinical Labs Introduces Diagnostic Test That Assists in Early Detection of Lung Cancer Enzo Biochem's Clinical Labs Introduces Diagnostic Test That Assists in Early Detection of Lung Cancer
October 5 Leading clinicians support launch of innovative early detection programmes for prostate and lung cancers in the work place Leading clinicians support launch of innovative early detection programmes for prostate and lung cancers in the work place
May 30 Oncimmune (USA) Highlights the Stories of Three Patients Diagnosed with Early Stage Lung Cancer Oncimmune (USA) Highlights the Stories of Three Patients Diagnosed with Early Stage Lung Cancer
May 1 National Jewish Health, the Nation's Premier Respiratory Hospital, Announces Lung Cancer Screening Trial Using Blood Test and CT National Jewish Health, the Nation's Premier Respiratory Hospital, Announces Lung Cancer Screening Trial Using Blood Test and CT
April 19 Oncimmune (USA) Launches New and Improved Website Aimed to Educate Medical Professionals about the Benefits of EarlyCDT-Lung Oncimmune (USA) Launches New and Improved Website Aimed to Educate Medical Professionals about the Benefits of EarlyCDT-Lung
March 22 Major Lung Cancer Screening Trial announced by the NHS in Scotland Using an Innovative Blood Test, EarlyCDT-Lung Major Lung Cancer Screening Trial announced by the NHS in Scotland Using an Innovative Blood Test, EarlyCDT-Lung
Date Title Link/PDF
December 21 Oncimmune (USA) Experiences Increased Interest in EarlyCDT-Lung as Doctors Place New Emphasis on Lung Cancer Screening with CT, in Response to Landmark NLST Study Oncimmune (USA) Experiences Increased Interest in EarlyCDT-Lung as Doctors Place New Emphasis on Lung Cancer Screening with CT, in Response to Landmark NLST Study
December 13 Research Shows Screening with X-rays Does Not Significantly Reduce Lung Cancer Mortality, Highlights Need for Additional Cancer Detection Tools Including EarlyCDT-Lung Research Shows Screening with X-rays Does Not Significantly Reduce Lung Cancer Mortality, Highlights Need for Additional Cancer Detection Tools Including EarlyCDT-Lung
November 7 Oncimmune (USA) Recognizes Lung Cancer Awareness Month; Featuring 30 Individual Lung Cancer Stories Oncimmune (USA) Recognizes Lung Cancer Awareness Month; Featuring 30 Individual Lung Cancer Stories
October 18 Oncimmune (USA) Releases Educational Video Series in an Effort to Support National Lung Cancer Awareness Month Oncimmune (USA) Releases Educational Video Series in an Effort to Support National Lung Cancer Awareness Month
September 20 Oncimmune (USA) Receives Laboratory Permit to Begin Offering EarlyCDT-Lung in the State of New York Oncimmune (USA) Receives Laboratory Permit to Begin Offering EarlyCDT-Lung in the State of New York
August 23 HelloHaveYouHeard.com Establishes Remarkable Web Presence and Social Media Following HelloHaveYouHeard.com Establishes Remarkable Web Presence and Social Media Following
July 5 First Reportable Data of EarlyCDT-Lung Use in Clinical Practice Presented at IASLC World Conference on Lung Cancer First Reportable Data of EarlyCDT-Lung Use in Clinical Practice Presented at IASLC World Conference on Lung Cancer
June 8 The EarlyCDT-Lung, a Blood Test Which Aids in Lung Cancer Risk Assessment and Diagnosis, Reaches Two Year Anniversary of Commercial Release Date The EarlyCDT-Lung, a Blood Test Which Aids in Lung Cancer Risk Assessment and Diagnosis, Reaches Two Year Anniversary of Commercial Release Date
May 11 Oncimmune Announces Independent Research to be Conducted on their EarlyCDT-Lung Test - A Test Designed to Aid in Identifying Lung Cancer Oncimmune Announces Independent Research to be Conducted on their EarlyCDT-Lung Test - A Test Designed to Aid in Identifying Lung Cancer

PLEASE READ THE FOLLOWING STATEMENT CAREFULLY

Electronic versions of the materials you are seeking to access are being made available on this website by Oncimmune Holdings plc (the “Company”).

These materials are not directed to nor are they intended for access by persons located or resident in the United States, Australia, Canada, South Africa, Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.

None of the securities of Company discussed or referred to in the materials you are seeking to access have been registered under the US Securities Act or 1933, as amended (the “Securities Act”) and may not be offered, sold, pledged or otherwise transferred except (1) in an offshore transaction meeting the requirements of Rule 903 or Rule 904 of Regulation S under the Securities Act, (2) pursuant to an effective registration statement under the Securities Act, or (3) pursuant to an available exemption from the registration requirements of the Securities Act, in each case in accordance with all applicable securities laws.

By clicking the “SUBMIT” button below you confirm that you (1) have read and understood the information set out above, (2) agree to be bound by its terms, (3) are not located in the United States and do not have a registered address in, and are not resident or located in, Australia, Canada, South Africa or Japan and (4) are permitted under applicable law and regulation to proceed to the following parts of this website.

Please click on the button below to confirm that you have read, understood and agree with the disclaimer above.

Yes, I accept No, I don't accept